Esophageal cancer is a common cancer worldwide. In China, it is the 3th leading cancer in incidence and 4th in mortality[@b1]. In 2015, there were 477,900 new cases and 375,000 deaths of esophageal cancer in China[@b1]. Although the development of its multidisciplinary treatment, five-year overall survival (OS) for esophageal cancer is 15--35% and the prognosis remains poor[@b2]. The two main pathological subtypes of esophageal cancer are squamous cell carcinoma and adenocarcinoma. In China, esophageal squamous cell carcinoma (ESCC) accounts for over 90% of cases[@b3]. The 7th edition American Joint Committee on Cancer tumor-node-metastasis (AJCC TNM) staging system is used to distinguish the prognosis among different risk groups of ESCC patients. However, ESCC patients at the same TNM stage and received similar therapy usually had variable outcomes. Therefore, it is important to explore dependable prognostic factors.

In recent years, neutrophil, platelet and lymphocyte derived from the peripheral blood were significantly associated with tumor progression in various tumors[@b4][@b5][@b6]. Some indicators such as neutrophil lymphocyte ratio (NLR) based on neutrophil and lymphocyte, platelet lymphocyte ratio (PLR) based on platelet and lymphocyte, and monocyte lymphocyte ratio (MLR) have emerged as prognostic factors in many cancers, including ESCC[@b7][@b8][@b9][@b10]. These indicators only integrate two cells. Systemic immune-inflammation index (SII), based on peripheral lymphocyte, neutrophil, and platelet counts, was recently investigated as a prognostic marker in several tumors including hepatocellular carcinoma[@b11][@b12], colorectal cancer[@b13] and small cell lung cancer[@b14]. However, SII has not been reported in ESCC. In this study, we evaluated the prognostic value of SII in patients with ESCC who underwent radical surgery. We also explore whether SII has more advantages to predict the survival of ESCC population than NLR or PLR. To increase statistical power and to further elaborate on the possible prognostic impact of SII, both Cox's proportional hazards model analysis as well as propensity score matching (PSM) were applied.

Results
=======

Clinicopathological characteristics of Patient
----------------------------------------------

There were 696 males (76.0%) and 220 females (24.0%) with an age range of 37--84 years (median 60.0 years), of which 46 patients were well differentiated, 450 patients were moderately differentiated, and 420 patients were poorly differentiated. According to the 7th AJCC standard, there were 168 patients at stage 0-I, 395 patients at stage II and 353 patients at stage III. Other clinicopathological features are shown in [Table 1](#t1){ref-type="table"}. The median OS was 42 months (range, 3 to 146 months) and the rate of 3- and 5-year OS was 52.5% and 44.2%, respectively. Patients with SII \> 307 in complete datasets were more likely to be men (*P* = 0.022), poor differentiation (*P* = 0.004), advanced T stage (*P* \< 0.001), advanced N stage (*P* \< 0.001) and advanced AJCC TNM stage (*P* \< 0.001) ([Table 1](#t1){ref-type="table"}). Patients with NLR \> 1.7 showed the similar results. PLR \> 120 was only associated with advanced AJCC TNM stage (*P* = 0.015). MLR was associated with sex (*P* \< 0.001), T stage (*P* = 0.002) and AJCC TNM stage (*P* \< 0.001) in complete datasets ([Table 2](#t2){ref-type="table"}).

The prognostic significance of SII, NLR, PLR and MLR
----------------------------------------------------

The Kaplan-Meier survival analysis showed that high SII, PLR, NLR and MLR scores were all associated with poor OS in ESCC patients (*P* \< 0.001, *P* = 0.017, *P* = 0.001, *P* = 0.009, respectively) ([Fig. 1](#f1){ref-type="fig"}). The median OS was 76 months for patients with SII ≤ 307 and 36 months for patients with SII \> 307. In addition, patients with PLR ≤ 120 had a median OS of 53 months, whereas patients with PLR \> 120 had a median OS of 36 months. Patients with NLR ≤ 1.7 had a median OS with 68 months, compared with 36 months for the patients with NLR \> 1.7. Patients with MLR ≤ 0.28 had a median OS with 49 months, compared with 34 months for patients with MLR \> 0.28. Based on the univariate analysis, sex, histological grade, T stage, N stage, SII, PLR, NLR and MLR were identified as the significant prognostic factors ([Table 3](#t3){ref-type="table"}). It was found that SII, PLR, NLR and MLR were highly correlated and had the same factors. There four separate multivariate models (SII, PLR, NLR and MLR) were run to avoid problems with the presence of multicollinearity. Multivariate analyses demonstrated that histological grade, T stage, N stage, and SII were independent risk factors for OS ([Table 3](#t3){ref-type="table"}). Among SII, NLR, PLR and MLR, only SII was an independent risk factor for OS (HR = 1.24, 95% CI 1.01--1.53, *P* = 0.042). In addition, the discrimination ability of SII, PLR, NLR and MLR was compared by the AUC for OS. The AUC for SII was bigger than SII, NLR, PLR and MLR for predicting survival in patients with ESCC in 3-years and 5-years ([Fig. 2](#f2){ref-type="fig"}). It means SII is superior to NLR, PLR or MLR as a predictive factor in ESCC patients.

Propensity score matching analysis
----------------------------------

Considered the sex, histological grade, T stage, N stage and AJCC TNM stage were imbalance between SII ≤ 307 and SII \> 307 ESCC patients ([Table 1](#t1){ref-type="table"}), we applied a 1:2 PSM ratio to minimize these differences. In the PSM analysis, we selected 253 patients from SII ≤ 307 group with matched pairings of the 506 SII \> 307 patients using a nearest-neighbour algorithm. These clinicopathological characteristics were balanced and evenly distributed between these groups (all *P* \> 0.1) ([Table 1](#t1){ref-type="table"}). The Kaplan-Meier survival curves for the matched groups are shown in [Fig. 3](#f3){ref-type="fig"}. In the matched 759 patients' survival analysis, median OS was 76 months for SII ≤ 307 ESCC patients and 43 months for SII \> 307 ESCC patients. The 5-year survival was 55.4% in SII ≤ 307 ESCC patients versus 44.9% in SII \> 307 ESCC patients. In addition, the multivariate analyses showed SII still remained an independent predictor for OS (HR = 1.30, CI 1.05-1.60, *P* = 0.018) ([Table 4](#t4){ref-type="table"}).

Discussion
==========

Inflammation has been known as a hallmark feature of tumor[@b15]. The correlation between inflammation and tumor was first reported by Rudolf Virchow in 1863[@b16]. Recently, accumulating evidence has indicated that inflammation contributes to tumor development, progression and metastasis. Systemic inflammatory scores such as NLR, PLR and MLR have been found to be independent markers of prognosis in a variety of cancers, including ESCC[@b7][@b8][@b9][@b10]. A novel systemic inflammation score-SII, based on neutrophil, platelet, and lymphocyte counts, was shown to be an independent risk of recurrence and survival for hepatocellular carcinoma, small cell lung cancer, colorectal cancer and gastric cancer patients[@b11][@b12][@b13][@b14][@b17]. It was considered to be better than PLR and NLR, and was associated with higher circulating tumor cells (CTCs) levels. In the present study, SII was confirmed to be a novel independent predictor of survival for patients with resectable ESCC by a multivariable Cox regression analysis and PSM analysis. It was shown to be superior to NLR, PLR and MLR as a predictive factor in ESCC patients. Compared with other prognostic factors, the inflammation-based prognostic scores are simple, inexpensive and routinely performed in clinical practice. Meanwhile, SII based on standard laboratory measurements of total platelet, neutrophil, and lymphocyte counts is simple, inexpensive and routinely performed in clinical practice. Thus, there is a potential for SII to be used as a marker for prognosis and treatment response surveillance.

Several potential mechanisms may be used to explain the prognostic values of SII in tumor. Cancer-mediated myelopoiesis has been recognised in the promotion of tumor angiogenesis, cell invasion, and metastasis in recent years. In contrast with myelopoiesis during acute infection, stress, or trauma in which circulating immune cells are transient increase, cancer myelopoiesis is associated with persistence of immature myeloid cells[@b18]. Firstly, neutrophils are not released from the bone marrow until mature ordinarily, however, in the context of inflammation, they were triggered by secretion of cytokines and chemokines, such as interleukin-6 (IL-6), tumor necrosis factor (TNF) and myeloid growth factors[@b19]. These inflammatory mediators enhance the invasion, proliferation, and metastasis of cancer cell, aid cancer cells to evade immune surveillance, and induce the resistance to cytotoxic drugs[@b6][@b20]. The elevated neutrophils can also release plenty of nitric oxide, arginase, and reactive oxygen species (ROS), leading to T cell activation disorders[@b21]. Secondly, platelets can protect CTCs from shear stresses during circulation, induce epithelial-mesenchymal transition, and promote tumor cell extravasation to metastatic sites[@b4][@b22]. Meanwhile, platelets and neutrophils have been reported to promote adhesion and seeding of distant organ sites through secreting vascular endothelial growth factor (VEGF)[@b5][@b11][@b23]. Thirdly, lymphocytes can also secrete several cytokines, such as IFN-γ and TNF-α, to control tumor growth and improve prognosis of cancer patients[@b24], and the decreased lymphocyte count and function will impair cancer immune surveillance and defense[@b6][@b24].

Based on the above theory, SII should be a more objective marker that reflects the balance between host inflammatory and immune response status than all the other systemic inflammation index such as the PLR and NLR. In fact, our results confirmed that SII is indeed superior to PLR, NLR and MLR. In addition, many studies have confirmed that non-steroidal anti-inflammatory drugs (NSAIDs) are associated with improved survival outcomes in patients with cancer, including esophageal cancer[@b25][@b26]. The patients with ESCC who have a high SII maybe especially benefit from targeted anti-inflammatory with aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).

Although our results demonstrated the prognostic value of SII in ESCC, there are still several limitations in this study. First, it should be noted that most patients with esophageal cancer in China are squamous cell carcinoma, while the most esophageal cancer is adenocarcinoma in western. Therefore, the prognostic significance of SII needs to be validated in patients with esophageal adenocarcinoma. Second, our study was a retrospective study, and there may be selection bias during retrospective data collection. However, we used PSM analysis which can minimize group differences in the baseline characteristics. Third, the majority (77.8%) of patients enrolled in this study had dissected lymph nodes with \<15, so further studies for patients with adequate lymphadenectomy are needed to confirm our results. Fourth, our study is a single retrospective center research study. Thus, a multicenter collaborative prospective study is required to be further verified in a prospective, large-scale collaborative study.

In conclusion, SII is a novel independent prognostic predictor for patients with ESCC undergoing radical esophagectomy. The prognostic value of SII is superior to PLR, NLR and MLR. Based on simple and inexpensive standard laboratory measurements, SII will be a potential marker for ESCC prognosis and treatment response surveillance.

Materials and Methods
=====================

Patients
--------

A retrospective analysis was conducted in patients who underwent radical esophagectomy at the Third Affiliated Hospital of Soochow University (Changzhou, China) from January 2002 to December 2012. The dissection area for lymphadenectomy was described as our previous article[@b27]. All patients received transthoracic radical esophagectomy with mediastinal and abdominal two-field lymphadenectomies. The scope of mediastinal lymphadenectomies included subcarinal, left and right bronchial, lower posterior mediastinum, pulmonary ligament, and paraesophageal and thoracic duct nodes. The scope of abdominal lymphadenectomies included the paracardial, lesser curvature, left gastric, common hepatic, celiac, and splenic nodes. The paratracheal and recurrent laryngeal nerve LNs were also dissected. Cervical lymphadenectomy was not conventionally performed, except for cases of suspicious cervical lymphadenopathy. The inclusion criteria were as follows: ESCC was confirmed by histopathology, R0 resection, no preoperative or postoperative radiotherapy and/or chemotherapy. At last, 916 patients were enrolled in the current study. The patient follow-up started from the date of surgery and continued up until December 2014 or patients' death. All the patients received postoperative follow-up every 3 months within two years after the operation, and the median follow-up time was 39 months (3--146 months). This study was undertaken according to the Declaration of Helsinki and was approved by the Ethics Committee of Third Affiliated Hospital of Soochow University. Written informed consent was obtained from all participants.

Data on preoperative peripheral neutrophil, lymphocyte, and platelet counts were extracted from the medical records. The definitions of SII, NLR and PLR are described as follows: SII = platelet\*neutrophil/lymphocyte; NLR = neutrophil/lymphocyte; PLR = platelet/lymphocyte. The optimal cutoff values including SII (SII ≤ 307, SII \> 307), NLR (NLR ≤ 1.7, NLR \> 1.7), PLR (PLR ≤ 120, PLR \> 120) and MLR (MLR ≤ 0.28, NLR \> 0.28) were determined by using X-tile software (<http://www.tissuearray.org/rimmlab>)[@b28].

Statistical Analysis
--------------------

Statistical analysis was conducted with SPSS 22.0 (SPSS, Chicago, IL), Graphpad Prism 6.01 (La Jolla, CA, USA) and R software 3.2.5 (<http://www.r-project.org/>) with MatchIt packages. The correlations between the inflammation-based prognostic scores and clinicopathological characteristics were analyzed by the χ^2^ test. Correlation analysis is using Person's correlation test. Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model. The time-dependent receiver operating characteristics (ROC) curve was used to compare the discrimination ability for OS. PSM was carried out because of imbalance in the baseline characteristics. PSM was done with a nearest-neighbour matching algorithm, allowing a maximum tolerated difference between propensity scores less than 30% of the propensity score SD. A *P* value less than 0.05 was considered to be statistically significant unless otherwise specified.
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###### Baseline characteristics for patients with SII ≤ 307 versus SII \> 307 before and after propensity matching.

  Clinical parameter               Unmatched (complete) dataset   Matched (1:2) dataset                                           
  ------------------------------- ------------------------------ ----------------------- ------- ------------- ----- ----- ------ -------
  Sex                                                                                     5.24     0.022^\*^                2.33   0.127
   Male                                        179                         517                                  179   384             
   Female                                       74                         146                                  74    122             
  Age                                                                                     0.10       0.921                  0.17   0.681
   ≤60                                         125                         330                                  125   242             
   \>60                                        128                         333                                  128   264             
  Histological grade                                                                      12.34    0.002^\*^                1.50   0.472
   Well differentiated                          23                         23                                   23    39              
   Moderately differentiated                   116                         334                                  116   255             
   Poorly or not differentiated                114                         306                                  114   212             
  Tumor location                                                                          3.90       0.142                  3.08   0.214
   Upper                                        22                         35                                   22    28              
   Middle                                      164                         435                                  164   329             
   Lower                                        67                         193                                  67    149             
  T stage                                                                                 23.74   \<0.001^\*^               5.70   0.127
   0-T1                                         83                         125                                  83    125             
   T2                                           64                         161                                  64    149             
   T3                                          101                         363                                  101   222             
   T4                                           5                          14                                    5    10              
  Examined lymph nodes                                                                    2.61       0.271                  2.24   0.326
   ≤5                                           58                         141                                  58    111             
   6--15                                       148                         366                                  148   277             
   \>15                                         47                         156                                  47    118             
  N stage                                                                                 9.96     0.019^\*^                3.65   0.302
   N0                                          150                         322                                  150   272             
   N1                                           62                         208                                  62    156             
   N2                                           28                         104                                  28    57              
   N3                                           13                         29                                   13    21              
  7^th^ AJCC stage                                                                        27.94   \<0.001^\*^               4.44   0.109
   0-I                                          74                         94                                   74    114             
   II                                           97                         298                                  97    223             
   III                                          82                         271                                  82    169             

SII: systemic immune-inflammation index; AJCC: American Joint Committee on Cancer.

###### Relationship between NLR, PLR or MLR and clinicopathological characteristics of patients with esophageal squamous cell carcinoma.

  Clinical parameter               NLR   PLR    MLR                                                                                                                              
  ------------------------------- ----- ----- -------- --------------------------------------- ----- ----- -------- --------------------------------------- ----- ----- -------- ---------------------------------------
  Sex                                          15.44    \<0.001^[\*](#t2-fn1){ref-type="fn"}^                0.38                    0.536                               52.93    \<0.001^[\*](#t2-fn1){ref-type="fn"}^
   Male                            193   503                                                    344   120                                                    330   366                               
   Female                          97    123                                                    114   106                                                    166   54                                
  Age                                           0.33                    0.565                                0.35                    0.552                                2.80                    0.094
   ≤60                             140   315                                                    223   232                                                    259   196                               
   \>60                            150   311                                                    235   226                                                    237   224                               
  Histological grade                            8.04     0.018^[\*](#t2-fn1){ref-type="fn"}^                 3.32                    0.190                                5.82                    0.054
   Well differentiated             23    23                                                     29    17                                                     32    14                                
   Moderately differentiated       143   307                                                    223   227                                                    248   202                               
   Poorly or not differentiated    124   296                                                    206   214                                                    216   204                               
  Tumor location                                8.85     0.012^[\*](#t2-fn1){ref-type="fn"}^                 0.54                    0.764                                5.90                    0.052
   Upper                           28    29                                                     28    29                                                     38    19                                
   Middle                          186   413                                                    295   304                                                    329   270                               
   Lower                           76    184                                                    135   125                                                    129   131                               
  T stage                                      22.21    \<0.001^[\*](#t2-fn1){ref-type="fn"}^                6.67                    0.083                               14.56     0.002^[\*](#t2-fn1){ref-type="fn"}^
   0-T1                            90    118                                                    118   90                                                     133   75                                
   T2                              77    148                                                    116   109                                                    126   99                                
   T3                              118   346                                                    216   248                                                    230   234                               
   T4                               5    14                                                      8    11                                                      7    12                                
  Examined lymph nodes                          0.24                    0.888                                0.02                    0.991                                1.42                    0.491
   ≤5                              63    136                                                    99    100                                                    107   92                                
   6--15                           160   354                                                    258   256                                                    286   228                               
   \>15                            67    136                                                    101   102                                                    103   100                               
  N stage                                      10.04     0.003^[\*](#t2-fn1){ref-type="fn"}^                 5.15                    0.161                                2.95                    0.399
   N0                              171   301                                                    247   225                                                    267   205                               
   N1                              72    198                                                    131   139                                                    139   131                               
   N2                              30    102                                                    56    76                                                     66    66                                
   N3                              17    25                                                     24    18                                                     24    18                                
  7^th^ AJCC TNM stage                         26.39    \<0.001^[\*](#t2-fn1){ref-type="fn"}^                8.43     0.015^[\*](#t2-fn1){ref-type="fn"}^                26.39    \<0.001^[\*](#t2-fn1){ref-type="fn"}^
   0-I                             81    87                                                     101   67                                                     81    87                                
   II                              114   281                                                    188   207                                                    114   281                               
   III                             95    258                                                    169   184                                                    95    258                               
  SII                                          304.85   \<0.001^[\*](#t2-fn1){ref-type="fn"}^               229.49   \<0.001^[\*](#t2-fn1){ref-type="fn"}^               84.56    \<0.001^[\*](#t2-fn1){ref-type="fn"}^
   ≤307                            190   63                                                     229   24                                                     199   54                                
   \>307                           100   563                                                    229   434                                                    297   366                               
  PLR                                          107.56   \<0.001^[\*](#t2-fn1){ref-type="fn"}^                                                                            81.33    \<0.001^[\*](#t2-fn1){ref-type="fn"}^
   ≤120                            218   240                                                                                                                 316   142                               
   \>120                           72    386                                                                                                                 180   278                               
  NLR                                           ---                      ---                                107.56   \<0.001^[\*](#t2-fn1){ref-type="fn"}^               160.87   \<0.001^[\*](#t2-fn1){ref-type="fn"}^
   ≤1.7                            ---   ---                                                    218   72                                                     246   44                                
   \>1.7                           ---   ---                                                    240   386                                                    250   376                               
  MLR                                          160.87   \<0.001^[\*](#t2-fn1){ref-type="fn"}^               81.33    \<0.001^[\*](#t2-fn1){ref-type="fn"}^                ---                      ---
   ≤0.28                           246   250                                                    316   180                                                    ---   ---                               
   \>0.28                          44    376                                                    142   278                                                    ---   ---                               

SII: systemic immune-inflammation index; PLR: platelet lymphocyte ratio; NLR: neutrophil lymphocyte ratio; MLR: monocyte lymphocyte ratio; AJCC: American Joint Committee on Cancer.

###### Univariate and multivariate cox regression analyses for overall survival in patients with esophageal squamous cell carcinoma (unmatched complete datasets).

  Variables                        Univariate analysis           Multivariate analysis                              
  ------------------------------- --------------------- --------------------------------------- ------------------- ------------------------------------------------------------------
  Sex                                                                                                               
   Male vs. Female                  1.39 (1.12--1.73)     0.003^[\*](#t3-fn1){ref-type="fn"}^    1.15 (0.93--1.44)                  0.206^[a](#t3-fn1){ref-type="fn"}^
  Age                                                                                                               
   ≤60 years vs. \>60 years         1.12 (0.94--1.33)                    0.207                                                                       
  Histological grade                                     \<0.001^[\*](#t3-fn1){ref-type="fn"}^                       \<0.001^[\*](#t3-fn1){ref-type="fn"}[a](#t3-fn1){ref-type="fn"}^
   Well differentiated                    Ref.                            ---                          Ref.                                          
   Moderately differentiated        3.96 (1.87--8.40)                   \<0.001                  2.29 (1.06--1.49)                                0.034
   Poorly or not differentiated    6.23 (2.94--13.20)                   \<0.001                  3.20 (1.49--6.86)                                0.003
  Tumor location                                                         0.708                                                                       
   Upper                                  Ref.                                                                                                       
   Middle                           1.04 (0.72--1.50)                    0.855                                                                       
   Lower                            0.95 (0.64--1.41)                    0.802                                                                       
  T stage                                                \<0.001^[\*](#t3-fn1){ref-type="fn"}^                       \<0.001^[\*](#t3-fn1){ref-type="fn"}[a](#t3-fn1){ref-type="fn"}^
   0-T1                                   Ref.                            ---                          Ref.                                          
   T2                               1.74 (1.28--2.38)                   \<0.001                  1.38 (1.01--1.90)                                0.045
   T3                               3.30 (2.52--4.31)                   \<0.001                  2.08 (1.48--2.94)                               \<0.001
   T4                               4.75 (2.71--8.35)                   \<0.001                  3.38 (1.79--6.40)                               \<0.001
  Examined lymph nodes                                                   0.158                                                                       
   ≤5                                     Ref.                            ---                                                                        
   6--15                            0.96 (0.77--1.19)                    0.679                                                                       
   \>15                             1.18 (0.91--1.52)                    0.208                                                                       
  N stage                                                \<0.001^[\*](#t3-fn1){ref-type="fn"}^                       \<0.001^[\*](#t3-fn1){ref-type="fn"}[a](#t3-fn1){ref-type="fn"}^
   N0                                     Ref.                                                         Ref.                                          
   N1                               2.13 (1.73--2.62)                   \<0.001                  1.66 (1.34--2.06)                               \<0.001
   N2                               3.82 (2.99--4.87)                   \<0.001                  2.68 (2.08--3.46)                               \<0.001
   N3                               5.45 (3.83--7.77)                   \<0.001                  4.23 (2.95--6.05)                               \<0.001
  SII                                                                                                               
   \>307 vs. ≤307                   1.44 (1.17--1.77)     0.001^[\*](#t3-fn1){ref-type="fn"}^    1.24 (1.01--1.53)    0.042^[\*](#t3-fn1){ref-type="fn"}[a](#t3-fn1){ref-type="fn"}^
  PLR                                                                                                               
   \>120 vs. ≤120                   1.23 (1.03--1.47)     0.020^[\*](#t3-fn1){ref-type="fn"}^    1.18 (0.99--1.40)                  0.070^[b](#t3-fn1){ref-type="fn"}^
  NLR                                                                                                               
   \>1.7 vs. ≤1.7                   1.35 (1.11--1.65)     0.002^[\*](#t3-fn1){ref-type="fn"}^    1.18 (0.97--1.44)                  0.107^[c](#t3-fn1){ref-type="fn"}^
  MLR                                                                                                               
   \>0.28 vs. ≤0.28                 1.26 (1.06--1.50)     0.010^[\*](#t3-fn1){ref-type="fn"}^    1.12 (0.94--1.34)                  0.220^[d](#t3-fn1){ref-type="fn"}^

SII: systemic immune-inflammation index; PLR: platelet lymphocyte ratio; NLR: neutrophil lymphocyte ratio; MLR: monocyte lymphocyte ratio; HR: hazard ratio; CI: confidence interval; Ref: reference. ^a^The variables (sex, histological grade, T stage, N stage and SII) were tested in a multivariate analysis. ^b^The variables (sex, histological grade, T stage, N stage and PLR) were tested in a multivariate analysis. ^c^The variables (sex, histological grade, T stage, N stage and NLR) were tested in a multivariate analysis. ^d^The variables (sex, histological grade, T stage, N stage and MLR) were tested in a multivariate analysis.

###### Univariate and multivariate cox regression analyses for overall survival in patients with esophageal squamous cell carcinoma (matched datasets, 1:2).

  Variables                        Univariate analysis           Multivariate analysis                              
  ------------------------------- --------------------- --------------------------------------- ------------------- ------------------------------------------------------------------
  Sex                                                                                                               
   Male vs. Female                  1.29 (1.02--1.63)     0.036^[\*](#t4-fn1){ref-type="fn"}^    1.12 (0.88--1.43)                                0.344
  Age                                                                                                               
   ≤60 years vs. \>60 years         1.14 (0.93--1.38)                    0.207                                                                       
  Histological grade                                     \<0.001^[\*](#t4-fn1){ref-type="fn"}^                                    \<0.001^[\*](#t4-fn1){ref-type="fn"}^
   Well differentiated                    Ref.                            ---                          Ref.                                          
   Moderately differentiated        3.81 (1.79--8.10)                    0.001                   2.10 (0.98--4.53)                                0.058
   Poorly or not differentiated    5.90 (2.77--12.53)                   \<0.001                  3.00 (1.39--6.45)                                0.005
  Tumor location                                                         0.540                                                                       
   Upper                                  Ref.                                                                                                       
   Middle                           0.89 (0.60--1.32)                    0.560                                                                       
   Lower                            0.81 (0.53--1.23)                    0.319                                                                       
  T stage                                                \<0.001^[\*](#t4-fn1){ref-type="fn"}^                                    \<0.001^[\*](#t4-fn1){ref-type="fn"}^
   0-T1                                   Ref.                            ---                          Ref.                                          
   T2                               1.69 (1.22--2.29)                    0.001                   1.33 (0.97--1.84)                                0.079
   T3                               3.33 (2.52--4.38)                   \<0.001                  2.11 (1.58--2.83)                               \<0.001
   T4                               4.08 (2.15--7.75)                   \<0.001                  2.44 (1.27--4.69)                                0.007
  Examined lymph nodes                                                   0.074                                                                       
   ≤5                                     Ref.                            ---                                                                        
   6--15                            0.93 (0.73--1.18)                    0.549                                                                       
   \>15                             1.28 (0.96--1.70)                    0.087                                                                       
  N stage                                                \<0.001^[\*](#t4-fn1){ref-type="fn"}^                                    \<0.001^[\*](#t4-fn1){ref-type="fn"}^
   N0                                     Ref.                                                         Ref.                                          
   N1                               2.43 (1.93--3.06)                   \<0.001                  1.78 (1.40--2.28)                               \<0.001
   N2                               4.39 (3.28--5.87)                   \<0.001                  3.12 (2.30--4.23)                               \<0.001
   N3                              6.89 (4.66--10.21)                   \<0.001                  5.63 (3.77--8.40)                               \<0.001
  SII                                                                                                               
   \>307 vs. ≤307                   1.31 (1.06--1.63)     0.014^[\*](#t4-fn1){ref-type="fn"}^    1.30 (1.05--1.62)   0.018^[\*](#t4-fn1){ref-type="fn"}\ [a](#t3-fn1){ref-type="fn"}^
  PLR                                                                                                               
   \>120 vs. ≤120                   1.17 (0.96--1.43)                    0.112                                                                       
  NLR                                                                                                               
   \>1.7 vs. ≤1.7                   1.30 (1.05--1.61)     0.016^[\*](#t4-fn1){ref-type="fn"}^    1.20 (0.97--1.49)                  0.093^[b](#t3-fn1){ref-type="fn"}^
  MLR                                                                                                               
   \>0.28 vs. ≤0.28                 1.19 (0.98--1.45)                    0.080                                                                       

SII: systemic immune-inflammation index; HR: hazard ratio; CI: confidence interval; Ref: reference. ^a^The variables (sex, histological grade, T stage, N stage and SII) were tested in a multivariate analysis. ^b^The variables (sex, histological grade, T stage, N stage and NLR) were tested in a multivariate analysis.

[^1]: These authors contributed equally to this work.
